and you, everyone. afternoon, Thank good Sara,
in also come to XXXX. BLA to highlight well license submission updates call Iovance LN-XXX year to preparation today's and important conference this during latest or on comment recent as toward as the progress a I am planned the milestones made pleased XXXX progress will lead XXXX. and I launch our application summarize and at in commercial biologics for lifileucel for
programs continued melanoma we our In XXXX, cancers. and tumor-infiltrating to advance in therapy TIL and cervical lymphocyte pivotal
tumors. for indications solid clinical studies X Phase initiated multiple also We in
as into blood lymphocyte introduced therapy addition, for peripheral PBL first approach new have blood we In cancers. a clinic our very or
on with an our melanoma. in therapy like metastatic TIL I'd begin lifileucel update to
of initiated study cohort we lifileucel. completed schedule X year a the This approximately United in announced We As patient C-XXX-XX cohort was in of common accounting each in annually XXXX that XX diagnosed target with States. have of pivotal skin the March a for reminder, last our of in and enrollment dosing X,XXX deaths melanoma cancer, is patients month ahead XX,XXX of type pivotal the patients.
We BLA. to be currently the before cohort plan followed in data from for months for patients cuts inclusion all on six X allowing
the assembling to have with expectedly used submit FDA for We We BLA XXXX. of to BLA. documents process the be meet the started in late plan and
regenerative As lifileucel therapy study. or and X a melanoma U.S. both, designations clinical which cohort the from Track RMAT the from medicine reminder, Fast supported was in received has FDA, by the data advanced
as of median months follow-up. melanoma median reach ORR the patient pretreated, survival X. late-stage The protocol recent study in for rate Immunotherapy enroll been same X for year. was last overall from in January presentations. to or in heavily most overall study cohort We to population XX XX.X% recent meeting. of November or in duration assessed XX.X cohort XXXX may We on at presented by data CITC in reached over annual reported of update of at was a cohort Iovance cohort Cancer, not who were X response the of several In patients still investigators. has presented data the X SITC DOR months. X not DOR response, Published The designed a update time a X corporate for was or ORR melanoma times the the reached shows patients The Society
lifileucel highly So, encouraging. the are of results
an XXXX. Iovance the We cohort as X to the organization continued updates of study additional on the in patients provide the to advancement for very-focused is toward BLA. in and preparation this hope from program monitor
is part enrolling metastatic complete cervical pivotal in Target dosing of track into in XXXX approximately cancer. We and LN-XXX enrollment is study study to remain midyear pivotal patients. second C-XXX-XX with continuing XX this the Our study. patients on
other, still planning of not later indication the submit on BLA to BLAs separately. two FDA. each be the dialogue each are are dependent Submission year, following the We and this with may a submitted
XXXX, Fast designation compelling These supported ORR Oncology FDA. in at as data the as XXXX. breakthrough demonstrating of a Track During Society designation designations annual meeting the study, were therapy which well from XX or ASCO LN-XXX of American BTD, June XX% the ongoing or was from presented patients by received Clinical in
FDA We XXXX. also X with meeting of Phase End in the successfully completed
the Following the order meeting, the LN-XXX. target support to registration in study to we patients of for pivotal XX increased enrollment part of
syndication. earlier this have We of LN-XXX includes therapy. changing pembrolizumab for a cohorts in combination with anticipation lines in cohort failed prior This new in patients cancer cohort who that with with also later and specifically added landscape allows patients anti-PD-X and cervical a in of treatment
dosed patients and program, than approximately we continues patients. clinical there robust second XX% XXX or a well our manufacturing Gen XXX one generation TIL XXXX, in During X to a of and demonstrated success more our rate over process be therapy is
in trials international capacity. melanoma building we the cervical, with manufacturing parallel for our already internal In pivotal and are
Specifically is manufacturing expect facility for XXXX. operational production continue aiming of launch, facility support partner build planned commercial supply to commercial continues. They facility is state-of-the-art meet Iovance of the capacity to patients. capability. AppTec we in our for be Philadelphia Construction from year-end Philadelphia this to WuXi foot our in The June come build to to started CMO commercial initial the by XXXX facility as a demand thousands will XXX,XXX internal expected square commercial Iovance XXXX-XXXX of in supply scale new
of of lifileucel medical continue In and LN-XXX, commercial and anticipation infrastructure. launch expanding we our affairs
patient remains focus main lifileucel. ensuring of experience Our positive area a of
are a we of in administering or and be items: by with with collaboration that, who HCPs, will operational in development product; engagement product; handling provision close payors. and launch; commercial excellence healthcare working the preparation Clinical site professionals for our of communication Towards following the Iovance on
in centers over cervical with experience cancers sites that lifileucel of initial for United launch with leaders anticipate prior number the and work melanoma for target for melanoma with currently and cervical. the we and be same clinical will the TIL those In LN-XXX We States, for XX key opinion and sites of approximately approval.
HCPs work to TIL to assure available is a and team affairs is about treating groups organizations. of with network place to information that interested advocacy medical in patient Our
continue our also only our in logistics place program not but assure also clinical for patient is infrastructure optimizing commercialization. organization to a and focused We for
We have made of with that we great work clinical expect centers in and commercializing them progress in collaborate in program identification with TIL. the to
payers way. of the to reimbursement In access initial to at patient we and patients. support patient the initiated And with intend access and to infusion. centric under On from TIL CMS discussions therapy model, reflection private to patient the process have timely ensure a we front, the every step for
market our to the on our continues, providing preparation launch and research As commercial we throughout forward plan year. look updates
our now Friedrich update our Officer, provide I other Chief would Medical about Finckenstein, clinical programs and like Friedrich? an Iovance? ask to at ongoing to research
